TOKENPOST
1 min read
Add as a preferred source on Google

Verastem Oncology Names Michael Bailey as CEO, Prices $250 Million Offering

Shares climbed around 20% in premarket trading Wednesday, Oct. 14. Bailey’s appointment takes effect Jan. 1, 2027.

By John Kim
Published
A document folder rests on an unmarked reception counter in afternoon light / TokenPost.ai
A document folder rests on an unmarked reception counter in afternoon light / TokenPost.ai

Verastem Oncology named Michael Bailey as its next president and CEO and priced a stock offering expected to raise $250 million, while its shares climbed around 20% in premarket trading Wednesday, Oct. 14.

Bailey is scheduled to take both roles effective Jan. 1, 2027.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…